Use of equol for treating androgen mediated diseases
Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.
1. A method of modulating androgen hormone action to ameliorate or enhance at least one condition of the skin or hair of a subject, comprising administering a composition comprising a racemic equol, wherein the racemic equol binds free 5α-dihydrotestosterone and inhibits its binding with the androgen receptor, and wherein ameliorating or enhancing at least one condition of the skin or hair of a subject comprises at least one of:
a) enhancing skin integrity
b) ameliorating or diminishing acne,
c) enhancing anti-photo-aging and skin anti-aging,
d) boosting extracellular matrix proteins,
e) diminishing scalp hair loss, or
f) enhancing the retention of scalp hair in male or female pattern baldness.
2. The method of claim 1 , wherein the composition is an oral composition comprising a dose sufficient to produce a concentration of the racemic equol in the bloodstream of the subject of at least about 0.2 mg equol per kg weight of the subject.
3. The method of claim 1 , wherein the composition is a topical composition comprising from about 0.1% to about 10% racemic equol.
4. The method of claim 1 , wherein the composition is a topical or subdermal composition comprising from about 0.1% to about 10% for diminishing scalp hair loss or enhancing the retention of scalp hair.
5. The method of claim 1 , wherein the composition further comprises a pharmaceutical active or an excipient.
6. The method of claim 1 , wherein the administerin is topically, transdermally, or subdermally.
7. The method of claim 1 , wherein the composition is in a delayed or sustained release formulation.
8. The method of claim 1 , wherein the administering is via a lotion, a spray solution, a foam solution, a pad, a bandage, or a transdermal patch.
9. A method of modulating androgen hormone action to ameliorate or enhance at least one condition of the skin or hair of a subject, comprising administering a composition comprising a racemic equol, wherein the racemic equol binds free 5α-dihydrotestosterone and inhibits its binding with the androgen receptor, and wherein ameliorating or enhancing at least one condition of the skin or hair of a subject comprises at least one of:
a) enhancing skin integrity
b) ameliorating or diminishing acne,
c) enhancing anti-photo-aging and skin anti-aging,
d) boosting extracellular matrix proteins,
e) diminishing scalp hair loss, or
f) enhancing the retention of scalp hair in male or female pattern baldness.
10. The method of claim 9 , wherein the composition is an oral composition comprising a dose sufficient to produce a concentration of the racemic equol in the bloodstream of the subject of at least about 0.2 mg equol per kg weight of the subject.
11. The method of claim 9 , wherein the composition is a topical composition comprising from about 0.1% to about 10% racemic equol.
12. The method of claim 9 , wherein the composition is a topical or subdermal composition comprising from about 0.1% to about 10% for diminishing scalp hair loss or enhancing the retention of scalp hair.
13. The method of claim 9 , wherein the composition further comprises a pharmaceutical active or an excipient.
14. The method of claim 9 , wherein the administering is topically, transdermally, or subdermally.
15. The method of claim 9 , wherein the composition is in a delayed or sustained release formulation.
16. The method of claim 9 , wherein the administering is via a lotion, a spray solution, a foam solution, a pad, a bandage, or a transdermal patch.